PL1758852T3 - Podstawione związki cyklopentenu - Google Patents

Podstawione związki cyklopentenu

Info

Publication number
PL1758852T3
PL1758852T3 PL05747867T PL05747867T PL1758852T3 PL 1758852 T3 PL1758852 T3 PL 1758852T3 PL 05747867 T PL05747867 T PL 05747867T PL 05747867 T PL05747867 T PL 05747867T PL 1758852 T3 PL1758852 T3 PL 1758852T3
Authority
PL
Poland
Prior art keywords
substituted cyclopentene
compounds
cyclopentene compounds
substituted
production
Prior art date
Application number
PL05747867T
Other languages
English (en)
Inventor
Oswald Zimmer
Michael Haurand
Klaus Schiene
Clemens Gillen
Johannes Schneider
Gregor Bahrenberg
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL1758852T3 publication Critical patent/PL1758852T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/56—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05747867T 2004-06-09 2005-06-07 Podstawione związki cyklopentenu PL1758852T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004027912A DE102004027912A1 (de) 2004-06-09 2004-06-09 Substituierte Cyclopenten-Verbindungen
US10/993,545 US7109214B2 (en) 2004-06-09 2004-11-19 Substituted cyclopentene compounds
PCT/EP2005/006092 WO2005121078A2 (de) 2004-06-09 2005-06-07 Substituierte cyclopenten-verbindungen
EP05747867A EP1758852B1 (de) 2004-06-09 2005-06-07 Substituierte cyclopenten-verbindungen

Publications (1)

Publication Number Publication Date
PL1758852T3 true PL1758852T3 (pl) 2010-02-26

Family

ID=35449934

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05747867T PL1758852T3 (pl) 2004-06-09 2005-06-07 Podstawione związki cyklopentenu

Country Status (7)

Country Link
US (1) US7109214B2 (pl)
EP (1) EP1758852B1 (pl)
AT (1) ATE441630T1 (pl)
DE (2) DE102004027912A1 (pl)
ES (1) ES2332922T3 (pl)
PL (1) PL1758852T3 (pl)
WO (1) WO2005121078A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DK1539766T3 (en) * 2002-06-05 2017-04-03 Bristol Myers Squibb Co CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) * 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
ES2584907T3 (es) 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US20220387357A1 (en) * 2021-06-04 2022-12-08 Cytometix, Inc. Method of Dosing a Pain Therapeutic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
WO1995018799A1 (en) * 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6222048B1 (en) * 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO1997028121A1 (en) 1996-02-01 1997-08-07 Merck Frosst Canada Inc. Alkylated styrenes as prodrugs to cox-2 inhibitors
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
EP1251738B1 (en) 2000-02-04 2008-12-17 Theracos, Inc. Novel diphenylethylene compounds
US7211598B2 (en) 2002-06-28 2007-05-01 Nitromed, Inc. Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

Also Published As

Publication number Publication date
US20050272955A1 (en) 2005-12-08
WO2005121078A3 (de) 2006-03-23
US7109214B2 (en) 2006-09-19
ES2332922T3 (es) 2010-02-15
EP1758852B1 (de) 2009-09-02
DE502005008057D1 (de) 2009-10-15
EP1758852A2 (de) 2007-03-07
ATE441630T1 (de) 2009-09-15
WO2005121078A2 (de) 2005-12-22
DE102004027912A1 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
MXPA05009068A (es) Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
SE0401762D0 (sv) Novel compounds
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
PL1853602T3 (pl) Związki chemiczne
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MX2008000255A (es) Activadores de urea glucocinasa.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
TW200738659A (en) Novel compounds
TW200639156A (en) New compounds
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
TW200635917A (en) Novel compounds
TW200745122A (en) New compounds I
MXPA05012679A (es) Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
TW200605888A (en) Novel compounds
TW200635916A (en) Compounds
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents